Please login to the form below

21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare

The 21st Century Cures Act has transformed the US drug development landscape. David Cooney explores the implications of the Act for pharmaceutical companies and reveals how it can be leveraged.
The 21st Century Cures Act was signed into law last December during the Obama administration. It brings numerous changes to the US drug development landscape, impacting patients, academia, research institutions, and industry.
Over the last number of months Blue Latitude have been engaging with US pharma companies to help our clients understand its implications and how it could be leveraged.

In this article, I will focus on the sections of the Act that relate specifically to communication around approved medical products and the impact it could have on the industry. Specifically, I will discuss the changes to medical product communications and how the FDA evaluates promotional materials that present information not contained in the labelling for the product. I believe this will increase collaboration between pharma and analytics.

Volume to value

The context for this change in policy is rooted in the evolution of healthcare from a volume to a value based market. For years, the priorities of drug development programmes were to prove the safety and efficacy of a drug in a placebo controlled, double-blind clinical trial that would support application for marketing authorisation.

These studies did not take into account the measures of performance requested today around value, such as rate of hospitalisation, cost per quality-added-life-year or patient reported outcomes, as these measures were not a prerequisite at time of trial design. 

Data illustrating the value of a drug is in high demand today, but repeating completed studies would incur substantial costs the industry is simply not willing/able to incur. Luckily, a lot of this data already exists. It exists in health records, patient registries, and claims databases, which, while uncontrolled, provide a huge sample set.

Enter the 21st Century Cures Act – which opens up credible sources of Real World Evidence (RWE) for commercial use to understand and communicate the value of medical products.


Consistency with FDA labelling

To be very clear, this is not a yard sale on data! There is still significant rigour required when using RWE commercially and adherence to the product prescribing information is critical.

The FDA  released guidance to add more detail on this matter. In it, the agency acknowledges that “labelling is the primary tool for communicating essential information needed for safe and effective use of the product ... it is not intended to be an exhaustive summary of all that is known about the product for its approved or clear uses.”

To support industry in determining whether communications about a product are consistent with the product’s FDA-required labelling, a three-factor system has been outlined. If a communication fails to satisfy any one of these factors, it is not consistent with the labelling.


Factor 1: Does the information in the communication compare to information about those conditions in the FDA-required labelling? (The answer to all must be yes)
  • Indication – Do the representations/suggestions about the product in the communication relate to a different indication than the one(s) reflected in the product’s FDA-required labelling?
  • Patient Population – Is the patient population represented or suggested in the communication outside the approved/cleared patient population reflected in the FDA-required labelling?
  • Limitations and Directions for Handling/Use – Do the representations/suggestions in the communication conflict with the use limitations or directions for handling, preparing, and/or using the product reflected in the FDA-required labelling?
  • Dosing/Administration – Do the representations/suggestions about the product conflict with the recommended dosage or use regimen, route of administration, or strength(s) (if applicable) set forth in the FDA-required labelling?


Download the full article from Blue Latitude Health

20th June 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and launch of precision medicines.
Blue Latitude Health
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in development. So how can pharma ensure its product stands out from the crowd?
Blue Latitude Health
How ready are you for launch?
Pharmaceutical launches are becoming more complex and competitive. Our launch excellence diagnostic tool helps you to map how ready you are for launch, while facilitating success in this challenging environment.
Blue Latitude Health
Does your pre-launch strategy really drive behaviour change?
One of the most interesting parts of a pharmaceutical launch is delving into the minds of stakeholders to understand why they behave in the way that they do. Blue Latitude Health Insight Consultant, Dorrotya Okros, examines how we use these insights to understand customers decision making behaviour, in order to make smarter business decisions.
Blue Latitude Health
Digitalising healthcare: what can the NHS learn from other industries?
Expensive digital solutions are often disregarded because they do not work well for the end user. Account Manager Fiona Grace explores this challenge and reveals the stories of innovation we can all learn from.
Blue Latitude Health
UK vs US: what makes a successful immunisation programme?
Emily Macdonald calls on her experience as a public health nurse specialising in the prevention of infectious disease in both the US and UK, to explore the differences between immunisation programmes in the two countries. She explores the challenges, opportunities for improvement, and asks why vaccination rates are falling.
Blue Latitude Health